C-19 Injections, Regulatory and Manufacturing Fraud

Evidence of collusion between the manufacturers, global regulatory agencies and the US Department of Defense

Sasha Latypova, September 30, 2022

Summary of All Evidence for C-19 Injections

- **Toxic by Design:** Mechanisms of injury designed into product
- **No Safety:** Horrific death and injury toll
- **No Efficacy:** Questionable to clearly negative efficacy
- **Bad Manufacturing:** Highly variable production, non-compliant with GMP, toxicity patterns, no enforcement of GMP
- **Malignant Policy:** Government lies, cover-up, gaslighting of the injured = clear intent to harm through forced nonsensical mandates

FDA Good Manufacturing Practices (cGMP): 21CFR210.1

- High quality, consistency and purity standards for drugs/vaccines:
  - Expectation that every new lot/batch is “almost the same” as all previous lots
  - Expectation that vaccines from different manufacturers for a disease indication are “the same” or interchangeable product
- Current GMP regulations were developed after several adulterated or poorly tested products poisoned and killed 100s of people (early 1900’s to 1960’s)
- “The failure to comply …shall render such drug to be adulterated …shall be subject to regulatory action”.

Historical Flu Vaccines: Consistent product across many manufacturers, lots, years



*Includes lots with non-zero SAE Reports only


C19 Vaccines Serious AE & Deaths/Valid Lot Number in US, as of 12/2021
Serious Events and Deaths (VAERS)
1,800
1,600
1,400
1,200
1,000
800
600
400
200
-
Pfizer
Moderna
Janssen
Flu vax data below this line
Range = 1-1544
939599
1805022
1816024
001C21A
004D21A
007D21A
011A21A
013A21A
016C21A
021B21A-1
024M20A
026C21A
029A21A
032F21A
036A21A
038D21A
040B21A
042B21A
045A21A
047E21A
051C21A
057D21A
066F21A
092D21A
208A21A
30155BA
EL0725
EL9262
EN6198
EN6208
ER8732
EW0161
EW0173
EW0185
EW0217
FC3180
FD7222
FF8841
CDC Verified Lot Numbers, Alphanumeric Sort


Pfizer: Deaths per 1000 doses by Lot by Date of Manufacture
VAERS Deaths (US) = 6282
Included in this analysis (match/known Lot#) = 5443
Even after adjustment for shipped lot size, enormous variability lot-to-lot remains unexplained
R² = 0.486
Expected Relationship R² = 0
Deaths per 1000 doses
0.12
0.10
0.08
0.06
0.04
0.02
0.00
8/7/2020
9/26/2020
11/15/2020
1/4/2021
2/23/2021
4/14/2021
6/3/2021
7/23/2021
9/11/2021
10/31/2021
12/20/2021
Date of Manufacture for the Lot Number

VAERS Deaths/100K after vaccination, by US State



Analysis by Douglas O'Connor

Evidence of Regulatory Fraud

From Non-Clinical Summaries Used for FDA Approval for Pfizer and Moderna Obtained via FOIA in March-April 2022.

The mRNA-1273 vaccine is currently being evaluated for safety and immunogenicity in a dose-ranging Phase 1 study (NCT04283461) sponsored by the Division of Microbiology and Infectious Diseases (DMID) of the National Institute of Allergy and Infectious Diseases (NIAID). The development of this vaccine is being accelerated as, if it is demonstrated to be safe and immunogenic, it may be used to address the current COVID-19 outbreak, as a result of the uniquely rapid and scalable manufacturing process for mRNA-1273.

2.4.1.3 Nonclinical Testing Strategy for mRNA-1273

The mRNA-1273 vaccine is currently being evaluated for safety and immunogenicity in a dose-ranging Phase 1 study (NCT04283461) sponsored by DMID under US investigational new drug (IND) application #19635. A letter from DMID authorizing the US Food and Drug Administration (FDA) to refer to IND #19635 to support review of this IND is provided in Module 1.4. In addition, nonclinical evaluations in mice are being conducted by the Vaccine Research Center (VRC) in parallel with the Phase 1 study. The interim data for these nonclinical studies are summarized in this document and are on file with the VRC.

Moderna's IND #19745

Pfizer and Moderna Avoided Major Categories of Standard Safety Testing



Moderna Documents Show:

- 50%+ studies with irrelevant test articles (not Spikevax mRNA)
- Biodistribution was studied with a concoction of 6 other irrelevant experimental products, from 2017
- Toxicology studies are all non-GLP, except 1 study (reproductive tox)
- Genotox and carcinogenicity in-vitro experiments for SM-102 only

mRNA medicines are platform-based





If mRNA works once, it will work many times

Under fabricated “crisis”, Pharma and FDA colluded to deceive the public by not testing mRNAs for safety and allowing mRNAs to be interchangeable without additional testing

moderna

Moderna presentation at JP Morgan conference in 2018

Results of Reproductive Tox Study in Rats: Moderna's Own Summary*

- Study detected "strong transfer of antibodies from dam to fetus and from dam to pup" and the levels were high in both:
  + mRNA/spike proteins (and not just antibodies) likely pass from mother to baby!
- Mothers experienced toxicity during gestation coinciding with the highest levels of antigen detected (day 13 of gestation):
  + Toxicity admitted as vaccine related by Moderna: Loss of fir, inability to use the hind limb, other non specified effects
  + Other toxicities and possibly deaths in the study are waived off by Moderna as "non-mRNA 1273 related"

*Full study report/data have not been made available for an independent review

Rat Offspring

Had Skeletal Malformations!

“mRNA-1273-related variations in skeletal examination included statistically significant increases in the number of F1 rats with 1 or more wavy ribs and 1 or more rib nodules. Wavy ribs appeared in 6 fetuses and 4 litters with a fetal prevalence of 4.03% and a litter prevalence of 18.2%. Rib nodules appeared in 5 of those 6 fetuses”.

“Maternal toxicity in the form of clinical observations was observed for 5 days following the last dose (GD 13), correlating with the most sensitive period for rib development in rats (GDs 14 to 17)”

mRNA-1273 was toxic to pregnant females and caused damage to the baby development during the same time

FDA Lied in the Label for Moderna Spikevax

4. Nonclinical Pharmacology/Toxicology

Developmental Assessment and Reproductive Toxicology (DART) Study
In a developmental toxicity study, 0.2 mL of a vaccine formulation containing nucleoside-modified mRNA (100 mcg) and other ingredients that are included in a 0.5-mL single human dose of SPIKEVAX was administered IM to female rats on four occasions: 28 and 14 days prior to mating, and on gestation days 1 and 13. No vaccine-related fetal malformations or variations and no adverse effect on postnatal development were observed in the study. Immunoglobulin G (IgG) responses to the pre-fusion stabilized spike protein antigen following immunization were observed in maternal samples and F1 generation rats indicating transfer of antibodies from mother to fetus and from mother to nursing pups.

FDA stating the opposite of Moderna's own finding in the label for Spikevax!

Pfizer Declared Product Label

Table P.1-1. Composition of BNT162b2 drug product, multi-dose vial (225 µg/vial).

Name of Ingredients	Reference to Standard	Function	Concentration (mg/mL)	Amount per vial	Amount per dose
BNT162b2 drug substance	In-house specification	Active ingredient	0.5	225 µg	30 µg
ALC-0315	In-h… speci…	F…	7.17	3.23 mg	0.43 mg
ALC-0159	In-hou…				0.05 mg
DSPC				0.7 mg	0.09 mg
Cholest…				1.4 mg	0.2 mg
Sucrose				46 mg	6 mg
Sodium chloride			6	2.7 mg	0.36 mg
Potassium chlo…		…nent	0.15	0.07 mg	0.01 mg
Dibasic sodium phosphate, dihydrate[b]	Ph. E…	…uffer component	1.08	0.49 mg	0.07 mg
Monobasic potassium phosphate[c]	Ph. Eur.	Buffer component	0.15	0.07 mg	0.01 mg
Water for Injection	Ph. Eur.	Solvent/vehicle	q.s.	q.s.	q.s.

NO VIALS FOUND CONFORMING TO THIS LABEL TO DATE!

No manufacturer or regulatory tests of ingredient conformity to label specified at the vial and dose level, i.e. “as dispensed” in CMC documents

Independent Testing of Vials by 26+ Teams Worldwide*

- RNA sequenced from some vials – RNA not conforming to label
- DNA and protein impurities detected in massive quantities
- Different heavy and rare metals of unknown origin or purpose:
  - Caesium, barium, cobalt, iron, chromium, titanium, cerium, gadolinium, aluminum, silicon, sulfur, thulium, antimony (Moderna).
- Large structures: blobs, particles, crystals, flat square shapes, fibers, ribbons, assembly and movement visible immediately from frozen state
- Different forms of graphene possible
- Leftover magnetic beads – remember fridge magnets sticking to people?

*https://www.ijvtpr.com/index.php/IJVTPR/article/view/52/83

RNA Sequenced from a Pfizer Vial



DNA



this kit is actually not suitable for plasmid DNA isolation; only for genomic DNA isolation. Still, I got also smaller DNA fragments.

there are no kits for simultaneous plasmid DNA and RNA isolation, as this is not needed in research.

Nucleic acid size distribution DNA of 15–30 kb†

DNA

Result:

the mRNA injections of Biontech and Moderna definitely contain DNA impurities

		~160 VAERS	~300 VAERS	~120 VAERS
	Biontech (1H048A) vial 1	**Biontech (1H048A) vial 2**	**Biontech (1F1010A)**	**Moderna (214015)**
ssDNA	~0.7ug per dose	~0.5ug per dose	~2.13ug per dose	~9ug per dose
dsDNA	~1.1ug per dose	~0.8ug per dose	n.a.	n.a.

Acceptance criteria: up to 9.9 ng per dose (Pfizer)

Actual tested: 1300 – 2100 ng per dose!!

4. Pfizer-Biontech samples in Neubauer Improved Chamber, at room temperature

A-C Upon insertion to the chamber. Viewed in Brightfield.

D-F After 20-30 minutes in the chamber. Viewed in Phase Contrast.
Filaments and structures started to form.



From Shimon Yanowitz, PhD

Visualisation of the extent of geometric objects in a 50uL drop of undiluted Pfizer Vaccine after 72 hours standing and examined at x100 Mag.



The Almost Good News: It's Safer When It's Broken





Figure 16: *Relationship between PEG polymerisation and vaccination side effects*

Inhomogeneous mRNA chains

Inhomogeneous PEG coating

Sources: Pfizer EMA CMC documents and vial tests by the German Working Group

The Reckless Scale of Manufacturing

- mRNA manufacturing is a challenge even at the mcg scale:
  - Low yields with loss of fidelity at every step:
    - 5 production steps with 80% yield = 30% final product yield (70% impurities)
    - 5 production steps with 60% yield = 7% final product yield (93% impurities)
  - Breakage of RNA, incomplete capping, tails fall off, LNPs not same size, LNPs break
  - Large % impurities from every manufacturing step not possible to remove well/fully
- Records show 200-300 liters and up to 900 (!) liters of product per batch:
  - Availability of raw materials is questionable at this scale
  - Chemical instability: enzymatic reaction reported seizing at 37.5 L in Pfizer docs
  - Large heterogeneity within the batch due to lipids-water separation
  - Filling heterogeneous product into tiny vials (0.45 ml) = increased heterogeneity at vial level resulting in “blanks” and “deadly shots”

Product cannot be made to conform with specification at this scale

Not in charge: Pharma companies ($$$$)

In charge: USG, DOD, HHS



Who is REALLY developing and manufacturing these injections?

As of October 20, 2020

OWS/BARDA Vaccine Manufacturing Portfolio



Mfg = ≥100M doses

The Bad News: “Vaccines” are a DOD Product

- DOD had established vaccine manufacturing capacity and “surge capacity” since at least 2012:
  - Millions of sq ft manufacturing capacity (e.g. Emergent, Ology, now Resilience)
  - Staff, raw materials, assays, kits, manufacturing equipment, etc.
- DOD-Pharma contracts for C-19 injections:
  - Dwarf any existing pharma product (~$10B first Pfizer contract)
  - No capacity to fulfill contracts in time except via DOD established contractors
  - No accountability other than “reasonable effort”
  - Micro-management of operations, clinical, regulatory from DOD (not “arms length”)
  - Product vials not serialized, shipped to DOD (not pharma distributor), “USG property” until injected
  - Product described explicitly as “civilian and military application”
- Pharma-foreign gov contracts:
  - Remove national sovereignty, prohibit changing of national laws
  - Prohibit batch or vial testing of imported product

In Conclusion:

- C-19 Injections are NOT pharmaceuticals
- US Government-Pharma collusion enabled violation of all established regulations and safeguards
- mRNA products are deadly by design and cannot be produced in compliance with cGMP at the current scale
- mRNA products must be stopped immediately
- Proper investigation and accountability for those responsible